Association of Vitamin D receptor gene polymorphisms and clinical/severe outcomes of COVID-19 patients
Infect Genet Evol. 2021 Oct 2 : 105098.doi: 10.1016/j.meegid.2021.105098
Rasoul Abdollahzadeh,a,⁎,1 Mohammad Hossein Shushizadeh,b,1 Mina Barazandehrokh,c Sepideh Choopani,d Asaad Azarnezhad,e,⁎ Sahereh Paknahad,a Maryam Pirhoushiaran,a S. Zahra Makani,f and Razieh Zarifian Yeganeha
Vitamin D Life wonders which is correct in this case
1) Health Problem ==> reduces VDR activation to protect itself (as had been documented for Breast Cancer, etc)
2) Reduced VDR ==> Lower Vitamin D in cell ==> Health Problem
Apparently they are unaware of the many safe, low-cost ways to improve VDR activation
Several of the ways have been proven to fight COVID-19 in Randomized Controlled Trials
- 26 health factors increase the risk of COVID-19 – all are associated with low vitamin D
- Many of these risk factors are also associated with a poor Vitamin D Receptor
Items in both categories VDR and Virus:
- COVID-19 symptoms and comorbidities associated with the type of Vitamin D Receptor – Oct 2021
- Enveloped virus infection (RSV, coronavirus, HIV, etc.) 1.5X more likely if poor Vitamin D Receptor – meta-analysis Dec 2018
- COVID-19 outpatients getting Quercetin nanoemulsion had excellent outcomes (Q increased Vitamin D in cells) – RCT – June 2021
- A virus that most adults have (Cytomegalovirus) decreases the amount of Vitamin D which gets to the cells – Jan 2017
- SARS-CoV-2 virus alters the activation of over 100 vitamin D related genes in the lung – April 2021
- Common sense COVID-19 risk reduction - masks, social distancing, vitamin D - Oct 2020
- AI is examining 170,000 potential COVID-19 treatments, Vitamin D is one of only 6 found – Sept 4, 2020
- Vitamin D Receptor activation should reduce ARDS associated with COVID-19 - June 2020
- Dengue viral production decreased 1000X if activate Vitamin D Receptor (in lab) – July 2020
- Vitamin D, Quercetin, and Estradiol all increase vitamin D in cells and increase genes which reduce COVID-19 – May 21, 2020
- Quercetin and Vitamin D - Allies Against COVID-19
- Risk of enveloped virus infection is increased 50 percent if poor Vitamin D Receptor - meta-analysis Dec 2018
- Hand, foot, and Mouth disease is 14X more likely if poor Vitamin D Receptor – Oct 2019
- Treating herpes reduced incidence of senile dementia by 10 X (HSV1 reduces VDR by 8X) – 2018
- Severe hand, foot, and mouth virus is 2.9 X more likely if poor Vitamin D receptor – Oct 2018
- Hepatitis B virus reduced by 5X the Vitamin D getting to liver cells in the lab – Oct 2018
- Some enveloped virus are 1.2 X more likely if have a poor Vitamin D Receptor -Aug 2018
- Severe Pertussis is 1.5 times more likely if poor vitamin D receptor – Feb 2016
- Dengue Fever associated with poor vitamin D receptor – July 2002
- Dengue virus 2X to 4X more likely if vitamin D receptor gene problems
Vitamin D Receptor category has the following
Vitamin D tests cannot detect Vitamin D Receptor (VDR) problems
A poor VDR restricts Vitamin D from getting in the cells
It appears that 30% of the population have a poor VDR (40% of the Obese )
Several diseases protect themselves by deactivating the Vitamin D receptor.Example: Breast Cancer
A poor VDR is associated with the risk of 55 health problems click here for details
The risk of 44 diseases at least double with poor VDR as of Oct 2019 click here for details
Some health problem, such as Breast Cancer reduce the VDR
VDR at-home test $29 - results not easily understood in 2016
There are hints that you may have inherited a poor VDR
Compensate for poor VDR by increasing one or more:
| Increasing | Increases |
| 1) Vitamin D supplement Sun, Ultraviolet -B | Vitamin D in the blood and thus in the cells |
| 2) Magnesium | Vitamin D in the blood AND in the cells |
| 3) Omega-3 | Vitamin D in the cells |
| 4) Resveratrol | Vitamin D Receptor |
| 5) Intense exercise | Vitamin D Receptor |
| 6) Get prescription for VDR activator paricalcitol, maxacalcitol? | Vitamin D Receptor |
| 7) Quercetin (flavonoid) | Vitamin D Receptor |
| 8) Zinc is in the VDR | Vitamin D Receptor |
| 9) Boron | Vitamin D Receptor ?, etc |
| 10) Essential oils e.g. ginger, curcumin | Vitamin D Receptor |
| 11) Progesterone | Vitamin D Receptor |
| 12) Infrequent high concentration Vitamin D Increases the concentration gradient | Vitamin D in the cells |
| 13) Sulfroaphane and perhaps sulfur | Vitamin D Receptor |
Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above
Far healthier and stronger at age 72 due to supplements Includes 6 supplements that help the VDR
Download the PDF from Vitamin D Life
Introduction: Growing evidence documented the critical impacts of vitamin D (VD) in the prognosis of COVID-19 patients. The functions of VD are dependent on the vitamin D receptor (VDR) in the VD/VDR signaling pathway. Therefore, we aimed to assess the association of VDR gene polymorphisms with COVID-19 outcomes.
Methods: In the present study, eight VDR single nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 500 COVID-19 patients in Iran, including
- 160 asymptomatic,
- 50 mild/moderate, and
- 90 severe/critical cases.
The association of these polymorphisms with severity, clinical outcomes, and comorbidities were evaluated through the calculation of the Odds ratio (OR).
Results: Interestingly, significant associations were disclosed for some of the SNP-related alleles and/or genotypes in one or more genetic models with different clinical data in COVID-19 patients.
Significant association of VDR-SNPs with signs, symptoms, and comorbidities was as follows:
- ApaI with shortness of breath (P ˂ 0.001)
- and asthma (P = 0.034) in severe/critical patients (group III);
- BsmI with chronic renal disease (P = 0.010) in mild/moderate patients (group II);
- Tru9I with vomiting (P = 0.031),
- shortness of breath (P = 0.04), and
- hypertension (P = 0.030);
- FokI with fever and hypertension (P = 0.027) in severe/critical patients (group III);
- CDX2 with shortness of breath (P = 0.022),
- hypertension (P = 0.036), and
- diabetes (P = 0.042) in severe/critical patients (group III);
- EcoRV with diabetes (P ˂ 0.001 and P = 0.045 in mild/moderate patients (group II)
- and severe/critical patients (group III), respectively).
However, the association of VDR TaqI and BglI polymorphisms with clinical symptoms and comorbidities in COVID-19 patients was not significant.
Conclusion: VDR gene polymorphisms might play critical roles in the vulnerability to infection and severity of COVID-19, probably by altering the risk of comorbidities. However, these results require further validation in larger studies with different ethnicities and geographical regions.
Clipped from PDF: Conclusion
Vitamin D has been shown to regulate macrophage responses, stopping them from producing excessive amounts of inflammatory cytokines and chemokines, which are common in COVID-19. Therefore, the prevalence and mortality rate of COVID-19 may depend on the modulatory effect of bioavailable Vitamin D levels of individuals, which is determined by the genetic background, such as VDR gene polymorphisms. Therefore, we designed the present study to explore the association of eight VDR gene SNPs with the clinical status and prognosis of COVID-19 patients.
We found significant associations of VDR gene variants with several clinical outcomes such as severity and shortness of breath in mild/moderate and severe/critical cases of COVID-19.
Nevertheless, the VDR gene SNPs could not be proposed as either independent or dependent risk factors to COVID-19-co-existing conditions, including hypertension, diabetes, asthma, cardiovascular disease, chronic renal disease, and malignancy.
Our data showed that some VDR SNPs have a clinical impact on the COVID-19 patients and might be helpful to identify the individuals at high risk of COVID-19 severity in the Iranian population. Moreover, the variations in the prevalence of COVID-19 and its mortality rates among countries may be explained by vitamin D function differed by the VDR polymorphisms. However, the present study is preliminary with partially limited sample size. Thus, further experiments are suggested to identify the role of VDR polymorphisms as the cause-effect of COVID-19 severity in a larger population, in other ethnicities and geographical regions.
| 46 visitors, last modified 09 Oct, 2021, |